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Unfortunately, the research effort directed into chronic obstructive pulmonary disease (COPD) has been
disproportionately weak compared to its social importance, and indeed it is the least researched of all common
chronic conditions. Tobacco smoking is the major etiological factor. Only 25% of smokers will develop “classic”
COPD; in these vulnerable individuals the progression of airways disease to symptomatic COPD occurs over two or
more decades. We know surprisingly little about the pathobiology of COPD airway disease, though small airway
fibrosis and obliteration are likely to be the main contributors to physiological airway dysfunction and these
features occur earlier than any subsequent development of emphysema. One potential mechanism contributing
to small airway fibrosis/obliteration and change in extracellular matrix (ECM) is epithelial mesenchymal transition
(EMT), so called Type-II EMT. When associated with angiogenesis (Type-III EMT) it may well also be a link with the
development of lung (airway) cancer which is closely associated with COPD. Active EMT in COPD may help to
explain why lung cancer is so common in smokers and also the core pathophysiology of small airway fibrosis.
Better understanding may lead to new markers for incipient neoplasia, and better preventive management of patients.
There is serious need to understand key components of airway EMT in smokers and COPD, and to demarcate novel
drug targets for the prevention of lung cancer and airway fibrosis, as well as better secondary management of COPD.
Since over 90% of human cancer arises in epithelia and the involvement of EMT in all of these may be a
central paradigm, insights gained in COPD may have important generalizable value.
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Epithelial mesenchymal transition (EMT) is a process in
which epithelial cells undergo a transition to a motile
mesenchymal phenotype [1]. It can be considered as a
marker of profound epithelial plasticity [2]. Elizabeth
Hay from Harvard University was the first to describe
the process of “epithelial mesenchymal transformation”
in 1982, and then in 1995 as an important process
involved in embryogenesis and organ development [3-5].
In the intervening time, the term “transformation” had* Correspondence: sssohal@utas.edu.au
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in any medium, provided the original work is pbeen replaced with the term “transition”, indicating
potential induction and reversibility of the process, even
potentially a two-way process from mesenchymal cells
to epithelium [6]. This reverse process has been termed
“mesenchymal-epithelial transition” (MET), but there
are very few examples of this in the literature and most
are concerned with embryogenic kidney formation [1].
The classically described process of EMT involves
phenotypic change and migration of epithelial cells into
the sub-epithelial mesenchyme in the lamina propria (LP)
to function as extracellular-matrix producing fibroblasts/
myofibroblasts [7-11]. EMT is a vital process during
embryogenesis (Type I EMT), but can also be induced as
a result of persistent damage and tissue inflammationOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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possibilities with active EMT: severe and even complete
organ fibrosis (Type II EMT), development of a pre-
malignant stroma when associated with angiogenesis
(Type III EMT) [1,7-16].
This complex process of EMT involves essential changes
in a wide range of proteins gained, maintained or attenu-
ated [13], but most of the studies reported in the literature
have been able to focus on only a few specific markers and
are likely to be far from complete. More importantly which
proteins/pathways are amendable to current therapeutics
and which will require new modalities of interaction are
not clearly understood. In this editorial we will focus on
recent advances made in evidence of active processes of
EMT in airway disease and its potential clinical importance
especially in COPD, and with the use of analysis of what
we know from other organ disease processes.
Main text
We recently published that EMT is an active process in
large airways of COPD patients [17,18]. Thus in smokers
but especially in current smoking COPD, epithelium is in
an activated state, staining strongly positive for epidermal
growth factor receptor (EGFR). At the same time, the
underlying reticular basement membrane (Rbm) is highly
fragmented with many clefts, which itself is a structural
change strongly suggestive of active EMT. Further the
clefts contain cells staining for “classic” EMT markers,
namely the proteolytic enzyme matrix-metalloproteinase-9
(MMP-9), mesenchymal markers including fibroblast pro-
tein S100A4 and vimentin and epithelial markers including
cytokeratin [17]. EMT-marker expressing cells are also
abundantly present in the basal epithelium (BE), and Rbm
cells stain positively for both epithelial and mesenchymal
markers [18]. Furthermore, the Rbm in large airways is
hyper-vascular [14-16] i.e. give the appearance of active
EMT type-III, and of course it is the large airways in COPD,
where cancer formation is common, especially squamous
cell carcinoma [1,6,7].
The other prime pathology associated with COPD is
small airway fibrosis and obliteration, and this could
potentially be related to active Type-II EMT at this site, if
such would be demonstrated [8-11]. It is suggested that
key players in fibrosis are fibroblasts/myofibroblasts
populations. The origin of these cells is still debated
in literature, if they are locally produced or bone
marrow derived, but, in some circumstances EMT has
been strongly implicated as a major source of these
cells and can significantly change ECM characteristics of
the airway wall. These changes in the ECM can alter the
stiffness characteristics of the airways, perhaps paradoxically
making them more floppy and vulnerable to expiratory
dynamic compression and obstruction during expiration
[19]. We believe that active EMT-Type-II is potentiallycontributing to these fibroblasts/myofibroblasts populations
in the small airways hence leading to ECM changes and
eventually leading to fibrosis/obliteration of these airways
[8-11]. Although there are substantial reports on extracellu-
lar matrix changes in other lung diseases such as interstitial
lung disease (ILD), idiopathic pulmonary fibrosis (IPF), and
asthma, investigations into changes in the ECM in COPD
patients are limited [19]. This warrants further studies.
Milara et al. did indeed recently report that EMT is an
active process also in small airways of COPD patients
and potentially contributing to small airway fibrosis [20].
In a separate study authors reported marked regression of
EMT by roflumilast N-oxide, a PDE4 inhibitor in bronchial
epithelial cells in vitro by restoring cellular cyclic adenosine
monophosphate (cAMP) levels [21]. Wang and colleagues
further elaborated this concept by demonstration of
increased Urokinase-type plasminogen activator receptor
(uPAR) expression, in the small airway epithelium of
patients with COPD, participating in an active EMT
process [22]. Authors also further demonstrated that
targeted silencing of uPAR using small hairpin RNA
(shRNA) inhibited cigarette smoke induced EMT in
human small airway epithelial cells. However, little
has yet been published as therapeutic potential to
block EMT in COPD airways apart from Wang and
Milara study which demonstrates so by restoring cAMP
and inhibiting uPAR [21,22].
We recently reported [23] in a randomized controlled
trial that inhaled corticosteroid fluticasone propionate
given over six months suppressed EMT-related changes
in large airways of COPD patients. This trial showed
marked reduction in Rbm fragmentation (core structural
hallmark of EMT), epidermal growth factor receptor
(EGFR), basal epithelial cell S100A4 expression and in
Rbm cell S100A4 and MMP-9 in the active inhaled corti-
costeroids (ICS) compared to placebo [23]. This is the first
study reporting anti-EMT effects of inhaled corticoste-
roids in COPD, where of course they are widely used as
putative “anti-inflammatory” agent, although that mode of
operation is far from convincing [24]. In human epidemio-
logical studies it is strongly suggested that patients on
inhaled corticosteroids, albeit only at high doses (as used
in our study), are associated with an appreciable (50%)
reduction in the risk of lung cancer [25-27]. We suggest
EMT might be the process by which this effect of ICS
occurs. If this is true, it has huge implications for thera-
peutic and public health policy, since it is strongly sug-
gested in literature that patients on ICS are associated
with a decreased risk for lung cancer. It is suggested that
statins may also have similar effects on EMT in COPD,
since lung cancer risk decreases in COPD patients who
are on statins [28], this warrants further studies.
We are not alone in recognising such possibilities. Thus,
recently in lung adenocarcinoma, vaccination against drivers
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against tumor progression, which is also attracting interest
from pharmaceutical industries and in fact adenocarcinoma
is now getting more common compared to squamous
cell carcinoma. The investigators developed an immuno-
therapeutic approach to target a major driver of EMT, the
T-box transcription factor T (also known as brachyury)
[29]. This therapeutic phenomenon is currently being
tested in patients with advanced carcinomas in the
context of a Phase I clinical trial [30,31]. This approach is
expected to generate an effective T-cell (CD8+) response
that selectively eradicates tumor cells expressing the EMT
driver of choice and undergoing EMT switch. When
employed in combination with conventional chemotherapy
eliminate epithelial tumor cells [29,30]. It is of interest and
relevance in this context that over 90% of human cancer
arises in epithelia (eg breast, colon, stomach, liver, prostate,
ovary/fallopian tube, bladder), and the involvement of
EMT in all of these may be a central paradigm [32-34].
COPD-related cancer may well be just another example of
this core principle of unstable epithelium in the context of
tissue inflammation and/or chronic stimulation [19].
In another study epigenetic based inhibition of EMT
by sorafenib has been reported in human lung epithelial
cells (A549, a lung adenocarcinoma cell line). Sorafenib
(Nexavar or BAY 43-9006) is a small molecular inhibitor
that targets a number of serine/threonine and receptor
tyrosine kinases, and is the first oral agent approved for the
clinical treatment of a variety of tumor types since 2005 by
the US Food and Drug Administration. In this study, the
authors reported that sorafenib inhibited TGF-β1-induced
EMT by increasing histone acetyltranferase (HAT)
expression and by decreasing histone deacetylase expres-
sion possibly via inhibition of Ras/Raf MAPK and ErbB sig-
naling [35]. Camera et al. also suggested TGF-β1/Smad2/3
as a potential therapeutic target for EMT [36]. Yang et al.
further demonstrated that crosstalk between muscarinic
acetylcholine receptor (mAChR) and TGF-β1 can lead to
EMT induction in lung epithelial cells (A549) suggesting a
role of non-neuronal cholinergic system in EMT and a
potential novel therapeutic target for EMT [37].
Byers and colleagues reported that in non-small cell
lung cancer (NSCLC) inhibition of Axl-RTK (another
receptor tyrosine kinase) by SGI-7079 lead to decrease in
growth of NSCLC tumors. The authors suggested Axl-RTK
as a potential therapeutic target for overcoming EGFR
inhibitor resistance associated with mesenchymal transition
[38]. Similar effects of sorafenib are observed in liver [39]
and urothelial carcinoma in situ [40] by targeting STAT3
and urokinase plasminogen activator (uPA). Recently in
idiopathic pulmonary fibrosis, efficacy of Nintedanib
(multiple tyrosine kinases inhibitor) and pirfenidone
(an anti-fibrotic and anti-inflammatory drug) has been
reported in improving lung function [41,42]. It is quitepossible that these drugs might also affect the process of
EMT or are inducing their therapeutic effect at least partly
by blocking EMT, since EMT has been shown to be
active in IPF [43]. Nintedanib works mainly by inhibiting
angiogenesis so it may have implications for EMT-Type-III
where angiogenesis is prominent and on the other hand
Pirfenidone is more anti-fibrotic in action so may have
implications for EMT-Type-II. These warrant further
studies, as they may have both anti-fibrotic and anti-cancer
effects through EMT.
Conclusions
EMT is an important process in airway disease especially
in smoking related COPD, where it might be contribut-
ing to small airway fibrosis and large airway epithelial
cancers. However there are very few studies reporting
anti-EMT effects of different drugs and data are especially
sparse from in vivo human clinical investigations. Most of
the conclusions are drawn from in vitro studies. Therapeutic
approaches to EMT are still in their infancy and we don’t
know which protein or pathways we should target to block
this profound epithelial plasticity. Given the fact that
disease-associated EMT is of two types, it becomes more
complicated to tease out what proteins/pathways are
contributing independently to fibrosis and cancer and
what therapeutic modalities will they require since BOTH
types share the EMT proteome, but empirically seem to
differ only in the neo-angiogenesis component.
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